1. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta- analysis 
Prof Ric N Price, MD, Lorenz von Seidlein, PhD, Neena Valecha, MD, Prof Francois Nosten, MD, Prof J Kevin Baird, PhD, Prof Nicholas J White, FRS 
The Lancet Infectious Diseases 
Volume 14, Issue 10, Pages (October 2014)
DOI: /S (14)
Copyright © 2014 Price et al. Open Access article distributed under the terms of CC-BY Terms and Conditions

2. Figure 1 Study selection
The Lancet Infectious Diseases  , DOI: ( /S (14) )
Copyright © 2014 Price et al. Open Access article distributed under the terms of CC-BY Terms and Conditions

3. Figure 2
Forest plot of the risk of recurrence at day 28 in patients treated with chloroquine or chloroquine plus primaquine
High dose >6 mg/kg. Low dose 3–5 mg/kg. Very low dose <2 mg/kg. As part of a sensitivity analysis, studies in which no recurrences were recorded before day 28 were assigned a numerator of 1, the derived odds ratio was recalculated as 0·43 (95% CI 0·24–0·79; p=0·006). References for all studies are shown in the appendix.
The Lancet Infectious Diseases  , DOI: ( /S (14) )
Copyright © 2014 Price et al. Open Access article distributed under the terms of CC-BY Terms and Conditions

4. Figure 3
Location of study sites with documented chloroquine-resistant (A) and chloroquine-sensitive Plasmodium vivax (B)
The Lancet Infectious Diseases  , DOI: ( /S (14) )
Copyright © 2014 Price et al. Open Access article distributed under the terms of CC-BY Terms and Conditions

5. Figure 4 Proportion of patients with parasitaemia on days 2 and 3
The Lancet Infectious Diseases  , DOI: ( /S (14) )
Copyright © 2014 Price et al. Open Access article distributed under the terms of CC-BY Terms and Conditions